JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - H.C. Wainwright raised its price target on Niagen Bioscience (NASDAQ:NAGE) to $12.00 from $11.00 on Monday, while maintaining a Buy rating on the stock. The company has demonstrated remarkable market performance, with a 253.82% return over the past year and an 83.41% gain year-to-date, according to InvestingPro data.
The price target increase follows Niagen Bioscience’s second-quarter 2025 financial results, which exceeded H.C. Wainwright’s expectations with revenue of $31.1 million compared to the firm’s forecast of $29 million, and earnings of $0.04 per share versus an estimated $0.02. InvestingPro data reveals strong fundamentals, with a healthy current ratio of 3.88 and impressive revenue growth of 35.89% over the last twelve months. Get access to 12 additional ProTips and comprehensive analysis with an InvestingPro subscription.
H.C. Wainwright revised its full-year 2025 revenue forecast to $125.6 million from $125.5 million, representing approximately 26.6% year-over-year growth. This aligns with Niagen Bioscience’s updated revenue growth guidance range of 22-27%, raised from the previous 20-25%.
For 2026, the research firm increased its full-year revenue estimate to $158 million from $150 million previously. The firm also adjusted its earnings forecasts upward, with full-year 2025 earnings per share now projected at $0.15 compared to $0.14 previously.
H.C. Wainwright’s 2026 earnings estimate for Niagen Bioscience was raised to $0.40 per share from the prior estimate of $0.34 per share.
In other recent news, Niagen Bioscience Inc. reported its second-quarter 2025 earnings, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $0.04, doubling the anticipated $0.02. Additionally, Niagen Bioscience reported revenue of $31.1 million, which exceeded projections by 9.66%. These results mark a positive development for the company, reflecting strong financial performance in the recent quarter. While the earnings announcement was followed by a rise in the company’s stock price, such movements are not the focus here. Investors may find these results encouraging, given the better-than-expected earnings and revenue figures. The company’s ability to outperform forecasts may draw attention from analysts and investors alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.